5results about How to "Binding block" patented technology

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.

The present application relates to the field of biological medicine, and specifically provides an anti-LILRB4 monoclonal antibody injection preparation, which comprises an anti-LILRB4 monoclonal antibody, a buffer salt, a protein protective agent, and a surfactant, wherein the pH of the injection preparation is 5.5-6.5. The injection preparation provided by the present application provides a good storage environment for the anti-LILRB4 monoclonal antibody through the synergistic interaction of different contents of the buffer salt, the protein protective agent, and the surfactant, and guarantees the biological activity of the anti-LILRB4 monoclonal antibody. The anti-LILRB4 monoclonal antibody can effectively inhibit the combination of the LILRB4 antigen and its ligand complex, thereby blocking the interaction with the ligand ApoE complex, preventing the activation of the downstream NF-kappa B signal pathway and the release of ARG1, preventing the inhibition of T cell proliferation and the promotion of tissue infiltration, and can be used for treating cancer.

Disclosed are an anti-LILRB2 nanobody, a nucleic acid encoding the nanobody, an expression vector comprising the nucleic acid, a pharmaceutical composition comprising the nanobody, and a use for preparing a medicament.

This invention discloses an anti-TL1A antibody or its antigen-binding fragment, its preparation method, and its applications, relating to the field of antibody technology. The antibody or its antigen-binding fragment of this invention comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises three complementary determinants HCDR1, HCDR2, and HCDR3 as shown in positions 31-35, 50-66, and 99-104 of SEQ ID NO:1, respectively; the light chain variable region comprises three complementary determinants LCDR1, LCDR2, and LCDR3 as shown in positions 24-35, 51-57, and 90-98 of SEQ ID NO:2, respectively. This antibody or its antigen-binding fragment exhibits excellent affinity and binding properties to the TL1A protein and can be used for the prevention and / or treatment of TL1A-mediated diseases.

This invention discloses an anti-LILRB2 nanobody, a nucleic acid encoding the nanobody, an expression vector containing the nucleic acid, a pharmaceutical composition containing the nanobody, and its use in preparing a pharmaceutical product.